Skip to main content

Table 2 The cumulative annual cost - effectiveness and cost – benefit of unsanctioned SIF in Vancouver using Jacobs et al.’s [24] model

From: Exploring the role of an unsanctioned, supervised peer driven injection facility in reducing HIV and hepatitis C infections in people that require assistance during injection

Variables

Annual cost of operation

Sharing rate

# of HIV averted

# of HCV averted

Cost-effectiveness ratio HCV

Cost-effectiveness ratio HIV

Benefit-cost ratio HCV

Benefit-cost ratio HIV

Cost-benefit ratio total

One SIF

$97,203

25 %

30

81

$1,200

$3,240

29.3

64.9

94.3

  

(33 %, 16 %)

(40, 20)

(103, 59)

($944, $1,648)

($2,430, $4,860)

(37.2, 21.3)

(86.6, 43.3)

(123.8, 64.7)

Two SIFs

$194,406

19 %

59

160

$1,215

$3,295

28.9

63.9

92.8

  

(26 %, 13 %)

(79, 38)

(207, 104)

($939, $1,869)

($2,460, $5,116)

(37.4, 18.8)

(85.6, 41.2)

(122.9, 60.0)

Three SIFs

$291,609

18 %

66

179

$1,629

$4,418

21.6

47.7

69.2

  

(24 %, 12 %)

(88, 44)

(237, 118)

($1,230, $2,471)

($3,314, $6,628)

(28.6, 14.2)

(63.5, 31.8)

(92.1, 46.0)

Four SIFs

$388,812

16 %

75

202

$1,925

$5,184

18.3

40.6

58.9

  

(22 %, 11 %)

(99, 50)

(266, 133)

($1,462, $2,923)

($3,927, $7,776)

(24, 12)

(53.6, 27.1)

(77.7, 39.1)

Five SIFs

$486,015

15 %

84

226

$2,151

$5,785

16.3

36.9

52.7

  

(19 %, 10 %)

(113, 56)

(311, 148)

($1,563, $3,284)

($4,301, $8,679)

(22.5, 10.7)

(49, 24.3)

(71.4, 35.0)

Six SIFs

$583,218

13 %

93

251

$2,323

$6,271

15.1

33.6

48.7

  

(18 %, 9 %)

(123, 62)

(325, 163)

($1,795, $3,578)

($4,741, $9,407)

(19.6, 9.8)

(44.4, 22.4)

(63.9, 32.2)

Seven SIFs

$680,421

12 %

102

274

$2,483

$6,671

14.2

31.6

45.7

  

(15 %, 8 %)

(135, 68)

(370, 177)

($1,839, $3,844)

($5,040, $1,006)

(19.1, 3.51)

(41.8, 21)

(61.0, 30.2)

  1. Note: The numbers in parentheses represent the results of the sensitivity analysis: (40 per cent sharing rate, 20 percent sharing rate)